This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Read more… 2025Health IT Predictions: Pharma. On the pharma front, expect an emphasis on AI for inventory management and targeted drugdevelopment , plus a shake-up in the market for weight-loss drugs. Read more… 2025 Predictions: Patient Experience. Happy 2025!
As we wrap up another year and get ready for 2025 to begin, it is once again time for everyone’s favorite annual tradition of Health IT Predictions! Check out the community’s predictions down below and be sure to follow along as we share more 2025Health IT Predictions !
In 2025, B2C2B models are poised to become increasingly prominent in healthcare, driven by several key factors: Digital Health Boom: The rapid growth of digital health technologies, such as telehealth, wearable devices, and AI-powered diagnostics, is creating new opportunities for B2C2B companies to reach both patients and healthcare providers.
CVC’s recent acquisition of the women’s health division of the Israeli drugdeveloper Teva for $800m created a company dedicated to contraception, fertility, menopause and osteoporosis. Recent analysis from Frost and Sullivan shows this market to be worth up to $50bn by 2025.
Transforming healthcare A report from the London School of Economics, The Role of Virtual Health Care and the Pharmaceutical Sector in Improving Population Health , published in 2021, forecast that the pharmaceutical industry would be a core player in all aspects from population health management to preventive and therapeutic care.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content